Hopantenic Acid
Homopantothenic acid · N-pantoyl-GABA · Calcium hopantenate · Pantogam · Pantogam Active · Pantocalcin · HOPA
Last updated
At a glance
Overview
Why Hopantenic Acid Earned Its Place in the Nootropic Toolkit#
Hopantenic acid is one of the quieter wins out of the Soviet-era nootropic pharmacopeia — a pantothenate-GABA hybrid that produces the rare combination of mild anxiolysis and cognitive activation without sedation, dependence, or the rebound problems that make phenibut a liability. Physique-focused users have adopted it for two specific reasons: a clean "clear-headed calm" for work and study blocks, and a non-addictive anxiolytic layer for managing the neurological noise that comes with aggressive cycles (tren insomnia, harsh-oral irritability, stimulant-driven tremor on a cut).
The mechanism is the interesting part. The pantoyl handle carries GABA across the blood-brain barrier — something free GABA cannot do — while simultaneously feeding into the acetyl-CoA pathway and upregulating cortical acetylcholine turnover. The result is GABAergic tone with cholinergic activation layered on top, which is why subjective reports describe it as "picamilon-like" or "aniracetam-like" rather than sedating. Clinical doses of 600–1200 mg/day have demonstrated measurable improvements in cognitive and anxiety endpoints over 12 weeks.
"Treatment with Pantogam Active at 600–1200 mg/day for 12 weeks led to significant improvements in cognitive and anxiety symptoms compared to baseline." — Medvedev et al., 2016
The sections below cover the documented hopantenic acid dosage ranges (250 mg starter through 2250 mg/day advanced), the practical differences between Pantogam and Pantogam Active, stack architecture for focus and on-cycle anxiolysis, the cholinergic side-effect profile, and the handful of contraindications — renal impairment and first-trimester pregnancy chief among them — that actually matter.
How Hopantenic Acid works
GABAergic Modulation Without Sedation#
Hopantenic acid is, structurally, a GABA molecule with a pantoyl handle bolted onto its amine — the handle's job is to smuggle GABA across the blood–brain barrier, which free GABA cannot cross in any meaningful quantity. Once central, the molecule acts as a low-affinity modulator at both GABA-A receptor–chloride-ionophore complexes and GABA-B receptors. Affinity is orders of magnitude below baclofen or benzodiazepines, which is the entire point: tonic inhibitory tone is increased enough to produce anxiolysis and anticonvulsant activity, but not enough to produce overt sedation, cognitive dulling, or the dependence/withdrawal liability that defines phenibut and baclofen.
"The mechanism of action of hopantenic acid includes both central GABAergic and cholinergic effects, which distinguishes it from the majority of other GABA derivatives." — Kopelevich VM, Gunar VI, Pharmaceutical Chemistry Journal, 1999
The practical translation: the subjective signature is "clear-headed calm" rather than the warm-blanket disinhibition of phenibut. For physique-focused users running harsh cycles — trenbolone, high-dose orals, aggressive cutting stacks — this is the more useful neuropharmacology, because it dampens cortical noise without compromising training focus or sleep architecture.
Cholinergic Facilitation#
This is the mechanism that separates hopantenic acid from every other GABA derivative and the one that drives its nootropic profile. The pantoyl portion of the molecule is structurally analogous to pantothenate — vitamin B5 — which is the obligate precursor to coenzyme A and therefore to acetyl-CoA, the substrate for acetylcholine synthesis. Hopantenic acid increases acetylcholine synthesis and turnover in cortex and hippocampus, and potentiates cholinergic transmission at the synaptic level.
The cognitive endpoints in the Russian clinical literature track this mechanism directly:
"Treatment with Pantogam Active at 600–1200 mg/day for 12 weeks led to significant improvements in cognitive and anxiety symptoms compared to baseline." — Medvedev VE et al., Zh Nevrol Psikhiatr Im S S Korsakova, 2016
Two practical consequences flow from the cholinergic mechanism. First, a co-administered choline source (alpha-GPC 300–600 mg, or CDP-choline 250–500 mg) provides substrate to match the upregulated turnover and is the single most reliable way to amplify the subjective effect. Second, the cholinergic activation has a circadian cost — a final dose taken after roughly 5 PM fragments sleep onset in a meaningful fraction of users. The dosing schedule earns its TID structure on this mechanistic basis.
Cerebral Metabolism and Hypoxia Tolerance#
Hopantenic acid increases brain glucose utilization and raises neuronal tolerance to hypoxic insult. The mechanism is incompletely characterized but appears to involve both the coenzyme-A pathway (via the pantoyl moiety entering one-carbon and acyl-transfer metabolism) and improved cerebral microcirculation. This is the basis for the registered indications in chronic cerebral ischemia, post-stroke recovery, and alcohol-induced encephalopathy.
For the physique audience the relevant translation is recovery from neurological stressors: heavy cutting phases, sustained sleep restriction, post-binge cognitive fog, and the cumulative cortical wear of long AAS cycles. A 1500 mg/day course over 2–4 weeks is the documented pattern for restoring cognitive baseline after these insults.
Indirect Dopaminergic Modulation#
Unlike direct dopaminergic agents, hopantenic acid does not bind dopamine receptors or alter dopamine synthesis at any meaningful rate. The dopaminergic effects are inferred from downstream outcomes — reduced tic severity, attenuation of motor automatism, improvement in extrapyramidal symptoms — and the working model is that increased GABAergic tone in striatal and basal-ganglia circuits modulates dopaminergic output indirectly.
"Hopantenic acid administered in doses from 1000 to 2000 mg/day showed efficacy in reducing tic severity and improving the overall neurological status." — Zykov VP, Kashirina EA, Naugol'nykh YuV, Zh Nevrol Psikhiatr Im S S Korsakova, 2004
The niche but useful application: users running stimulant-heavy cutting stacks (clenbuterol, ephedrine, high-dose caffeine with yohimbine) where fine-motor tremor becomes dose-limiting. A 500 mg BID floor alongside the stimulant phase typically flattens the tremor without flattening the thermogenic or appetite-suppressant effect — exactly the dissociation a competitive prep needs.
Anxiolysis Without HPG-Axis Footprint#
The final mechanistic point is what hopantenic acid does not do. It has no measurable interaction with the hypothalamic-pituitary-gonadal axis, no androgenic or estrogenic activity, no effect on prolactin, no documented impact on cortisol rhythm beyond the indirect downstream effect of reduced anxiety load, and no CYP-mediated interaction profile worth managing. It is fully orthogonal to AAS, SARM, peptide, and ancillary protocols.
This matters because the alternative anxiolytics that users reach for during harsh cycles — phenibut, alcohol, benzodiazepines — all carry meaningful costs: tolerance escalation, withdrawal liability, sleep-architecture disruption, and in the case of alcohol, frank antagonism of recovery and body composition. Hopantenic acid's GABAergic + cholinergic profile achieves the anxiolytic endpoint without any of those costs, and its mechanism makes it stackable with an SSRI for users already on one:
"Addition of 1200 mg/day hopantenic acid to standard SSRI therapy was associated with a faster therapeutic effect and enhanced anxiolytic activity." — Voznesenskaya TG et al., Zh Nevrol Psikhiatr Im S S Korsakova, 2017
| Mechanism | Primary Endpoint | Practical Translation |
|---|---|---|
| GABA-A / GABA-B low-affinity modulation | Anxiolysis, anticonvulsant tone | On-cycle calm without phenibut's tolerance liability |
| Cholinergic upregulation (via pantoyl/CoA pathway) | Cognition, focus, attention | Stack with alpha-GPC; dose by ~5 PM |
| Cerebral glucose utilization, hypoxia tolerance | Neuroprotection, recovery | Post-binge / post-cut cognitive rebuild |
| Indirect striatal GABA → dopamine modulation | Tic and tremor attenuation | Tames stimulant-induced tremor on cutting stacks |
| No HPG-axis activity | None — clean profile | Fully stackable with AAS, SARMs, ancillaries |
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 250–500 mg | 3× daily | Documented entry-level range |
| Mid | 500–1500 mg | 3× daily | Most commonly studied range |
| High | 1500–2250 mg | 3× daily | Divided 2–3× daily with the final dose by ~5 PM to avoid sleep fragmentation from cholinergic activation. Steady state reached in 2–3 days; subjective onset is gradual over 5–10 days. |
Cycle length & outcomes
Documented cycle
4–16 weeks
Plateau after
16 wks
Cycle Length & Protocol Design#
Hopantenic acid is a steady-state nootropic, not an acute stimulant. Subjective effects build gradually over 5–10 days as cholinergic turnover upregulates and GABAergic tone stabilizes — there is no "first-dose effect" to chase, and the compound rewards patience over escalation. Russian clinical practice runs continuous 1–4 month courses; the bodybuilding and looksmaxxing community typically mirrors this with light cycling for sensitivity preservation.
| Goal | Cycle Length | Daily Dose | Schedule |
|---|---|---|---|
| Sensitivity test / first exposure | 2–3 weeks | 250–500mg | 250mg AM + 250mg early PM |
| Cognitive focus block (study / work) | 6–8 weeks | 1000–1500mg | 500mg TID (last dose by 5 PM) |
| On-cycle anxiolytic (tren, harsh orals) | Run with the AAS cycle (8–12 wk) | 1000–1500mg | 500mg AM + 500–750mg early PM |
| Anxious-depression SSRI adjunct | 8–12 weeks | 1200mg | 600mg BID |
| Tic / stimulant-tremor management | 4–8 weeks | 1000–2000mg | 500mg TID–QID |
| Post-binge / alcohol cognitive recovery | 1–3 weeks | 1500mg | 500mg TID |
| Advanced short block | 4–8 weeks | 2000–2250mg | 750mg TID |
"Treatment with Pantogam Active at 600–1200 mg/day for 12 weeks led to significant improvements in cognitive and anxiety symptoms compared to baseline." — Medvedev VE et al., Zh Nevrol Psikhiatr Im S S Korsakova (2016)
Onset Timing & Steady State#
Plasma kinetics are fast — Tmax around 1.5 h, half-life ~6.7 h — but the subjective nootropic signal is slow. Steady state is reached within 2–3 days of TID dosing, but the cholinergic and GABAergic adaptation that drives the "clear-headed calm" phenotype takes 7–14 days to fully express. Users who abandon the protocol at day 3 because "nothing is happening" are quitting before the compound has done its work.
"After single oral administration, hopantenic acid reached a peak plasma concentration at 1.56 h and had an elimination half-life of 6.68 h in healthy volunteers." — Maslova OI, Eksp Klin Farmakol (2010)
A reasonable evaluation window is 14 days minimum at 1000–1500 mg/day before judging response. If there is no subjective signal by day 21, the compound is unlikely to be a strong responder for that subject.
Loading & Tapering#
No loading phase is required or beneficial. Front-loading does not accelerate the cholinergic adaptation that defines the effect — it just front-loads the mild rhinitis / hypersensitivity risk. Dosing begins at the target therapeutic dose from day one.
No taper is required at cycle end. Unlike phenibut or baclofen, hopantenic acid produces no GABA-B downregulation severe enough to generate a withdrawal syndrome, and abrupt discontinuation after 12+ week courses is well-tolerated in the clinical record. For long courses (>3 months), a one-week step-down (1500 → 1000 → 500 → 0) is a conservative habit but not pharmacologically necessary.
Dose-Response Plateau#
The dose-response curve flattens hard above ~1500–2000 mg/day. Pushing to the 3000 mg/day clinical ceiling buys mild fatigue and occasional GI complaints, not more nootropic effect. The advanced 2250 mg/day tier is reserved for short blocks (4–8 weeks) where a specific cognitive demand justifies the marginal return, or for tic/tremor indications where the published literature genuinely supports the higher exposure.
"Hopantenic acid administered in doses from 1000 to 2000 mg/day showed efficacy in reducing tic severity and improving the overall neurological status." — Zykov VP et al., Zh Nevrol Psikhiatr Im S S Korsakova (2004)
Cycling Strategy#
Tolerance is mild — far milder than phenibut, picamilon, or any racetam — and the clinical record supports continuous 1–4 month courses without dose escalation. Three practical patterns dominate:
- Continuous (clinical model): 8–16 weeks on, 4 weeks off. Best for cognitive / anxious-depression use-cases where steady-state effect is the point.
- Pulsed (community model): 6–8 weeks on, 2–4 weeks off. Conservative, preserves novelty, suits users who layer multiple nootropics.
- On-demand stack adjunct: Run only during specific AAS cycles or stimulant-cutting phases where the anxiolytic / anti-tremor effect is the goal. Discontinue when the parent cycle ends.
Bloodwork Cadence#
Hopantenic acid itself requires no compound-specific monitoring — no liver, lipid, or hormonal impact has been documented across decades of Russian clinical use. The one monitoring point worth tracking is renal function, because ~67% of the dose is cleared unchanged in urine:
- Baseline CMP prior to initiating a cycle ≥8 weeks, with attention to creatinine, eGFR, and BUN
- Repeat CMP at 12 weeks for continuous courses, or quarterly for chronic users
- Users running concurrent AAS cycles will already be pulling these panels — no additional draws required
"Addition of 1200 mg/day hopantenic acid to standard SSRI therapy was associated with a faster therapeutic effect and enhanced anxiolytic activity." — Voznesenskaya TG et al., Zh Nevrol Psikhiatr Im S S Korsakova (2017)
Stacking Within the Cycle#
Hopantenic acid runs cleanly alongside almost anything in the bodybuilding / looksmaxxing toolkit. The cholinergic upregulation pairs naturally with a choline source (alpha-GPC 300–600 mg/day) and with racetams (piracetam 1.6 g TID, aniracetam 750 mg BID) — the combination is the closest thing to a "Russian nootropic stack" with a credible clinical evidence base. For on-cycle anxiolytic duty, the addition of ashwagandha 600 mg and L-theanine 200 mg rounds out the cortisol/anxiety axis without sedation.
The combinations to avoid are also the obvious ones: phenibut is redundant (both hit GABA-B and the additive depression is real), baclofen doubles down on the same receptor pool, and heavy alcohol intake during a course compounds CNS depression and undermines the very encephalopathy-recovery use-case the compound is documented for.
Risks & mistakes
Common (most users)#
- Mild rhinitis or conjunctivitis — the most frequently reported reaction, usually transient and self-limiting within the first week. No mitigation typically needed; if persistent, dose is reduced or split into smaller increments.
- Transient skin rash — hypersensitivity-type, low incidence. Discontinue if it spreads or persists beyond a few days.
- Subjective "nothing happening" in the first 5–10 days — not a side effect per se but the most common reason users abandon the compound prematurely. Steady state takes 2–3 days; subjective onset is gradual. The protocol calls for a minimum 10–14 day evaluation window before judging response.
- Mild evening alertness or sleep fragmentation — a consequence of cholinergic activation when the final dose lands too late. Mitigation: the last dose is scheduled by ~5 PM, with the bulk of the daily total loaded into the morning and early afternoon.
Uncommon (dose-dependent or individual)#
- Headache — typically signals choline shortfall as cholinergic turnover increases. Mitigation: pair with alpha-GPC 300–600 mg/day or CDP-choline 250–500 mg/day.
- Mild GI upset (nausea, soft stool) — dose-dependent, usually at 2 g/day and above. Splitting into 3–4 smaller doses with food resolves it; otherwise the daily total is trimmed back toward 1.5 g.
- Tinnitus — rare, generally at the upper end of the dose range. Back off to the intermediate band (500 mg TID) if it appears.
- Paradoxical anxiety or irritability — occasional in individuals sensitive to cholinergic load. Reducing the dose or adding L-theanine 200 mg typically smooths it out; if not, the compound is discontinued.
- Fatigue / "flat" affect at supratherapeutic doses — the dose-response curve plateaus above ~1.5 g/day and pushing past 2.25 g often buys mild lethargy rather than more nootropic effect. Standard CMP every 3–4 months covers any renal drift on chronic high-dose protocols.
Rare but serious#
- Broader hypersensitivity reaction — the rhinitis/rash phenotype occasionally escalates into a more systemic allergic response. Any sign of facial swelling, urticaria beyond the trunk, or breathing changes warrants immediate discontinuation.
- Accumulation in undiagnosed renal impairment — ~67% of the dose is cleared unchanged in urine. Subjects with unrecognized CKD can accumulate to clinically meaningful levels; a baseline eGFR and creatinine reading is sensible prior to initiating a multi-month protocol.
- CNS depression when stacked with other GABAergics or alcohol — hopantenic acid potentiates barbiturates, benzodiazepines, baclofen, phenibut, and ethanol. Additive sedation has been documented; the combination is avoided rather than dose-adjusted.
No cases of dependence, withdrawal syndrome, hepatotoxicity, hematological abnormalities, or QT effects have been documented across decades of Russian and Eastern European registration data.
Hard contraindications#
- Acute or severe renal disease. Renal-cleared, unchanged. Accumulation in significant CKD is mechanistically certain.
- First-trimester pregnancy. Contraindicated per Russian labeling; no safety data exist.
- Documented hypersensitivity to hopantenic acid or pantothenate derivatives.
- Concurrent phenibut use. Redundant GABA-B activity, additive CNS depression, and no synergistic upside. The two are mutually exclusive in any sensible stack.
- Heavy alcohol use. Additive CNS depression and a fundamental incompatibility with a compound being run for cognitive recovery from alcohol exposure in the first place.
Gender, pregnancy, and PCT considerations#
Hopantenic acid is non-hormonal and dosing is identical across the subject pool — no HPG-axis activity, no androgenic or estrogenic signaling, no prolactin or cortisol effects, no virilization risk. It is fully compatible with concurrent AAS, SARM, and ancillary protocols and requires no PCT support, nor does it interfere with one.
The single gender-specific line is pregnancy: first-trimester exposure is contraindicated per the Russian registration, and safety data in lactation are absent. For female subjects of reproductive potential, the protocol is paused around any planned conception window.
"Treatment with Pantogam Active at 600–1200 mg/day for 12 weeks led to significant improvements in cognitive and anxiety symptoms compared to baseline." — Medvedev VE et al., Zh Nevrol Psikhiatr Im S S Korsakova (2016)
"Addition of 1200 mg/day hopantenic acid to standard SSRI therapy was associated with a faster therapeutic effect and enhanced anxiolytic activity." — Voznesenskaya TG et al., Zh Nevrol Psikhiatr Im S S Korsakova (2017)
Across the published 600–2000 mg/day clinical range, the adverse-event profile remains one of the cleanest in the GABA-derivative class — markedly better than phenibut, baclofen, or pregabalin on the dependence and withdrawal axes, and free of the hepatic and hematological monitoring burdens that follow most chronic nootropic protocols.
FAQ — Hopantenic Acid
Research & citations
5 studies cited on this page.
Conclusion
Hopantenic acid stands out as a mild, versatile nootropic with a unique GABA-cholinergic profile — favored for steady cognitive activation, anxiolysis, and clean stacking with other research compounds, especially in protocols focused on mood and focus.
Key takeaways:
- Standard dose: 500–1500 mg/day, divided 2–3× daily; the most common protocol is 500 mg with breakfast and lunch
- Oral route exclusively; final dose by ~5 PM is supported to avoid mild sleep disruption
- Effective cycle length: 4–16 weeks; tolerance buildup is minimal and deloads are short
- Stacks seamlessly with alpha-GPC, racetams, ashwagandha, or the classic Russian nootropic blends
- Headline benefit: smooth cognitive enhancement plus anxiolytic tone, suited for recomp, work/study blocks, and AAS-induced neuro side effects
- Side effect profile is benign; primary cautions are for severe renal disease and first-trimester pregnancy
For users seeking a nootropic edge without the drama of phenibut or stimulant fallout, hopantenic acid remains one of the most research-backed, forgiving options available for cognition and focus-driven stacks.